Emyria (EMD) Investor presentation summary

Market context and opportunity

• Mental health is the leading chronic health issue in Australia, with rising prevalence and significant fragmentation in service provision.

• Major funders, including private insurers and government, spend hundreds of millions annually on mental health, with Medibank and DVA as key payers.

• Australia is the first country to reschedule MDMA and psilocybin for psychiatric use, enabling new treatment pathways for PTSD and depression.

Business model and clinical approach

• Operates a national network of clinics targeting treatment-resistant PTSD and depression through the Authorised Prescriber Program.

• Delivers a protocol combining medication (MDMA or psilocybin) with ~90 hours of supervised intensive psychotherapy, at a cost of ~$10,000 per treatment cycle.

• Demonstrates strong clinical outcomes, with all work-related PTSD patients returning to employment six months post-treatment and over 66% no longer meeting PTSD criteria after 12 months.

Funding and partnerships

• Only provider partnered with Medibank for fully funded, uncapped MDMA-assisted therapy for PTSD and depression, with treatment in hospital settings.

• DVA funds psychedelic-assisted psychotherapy for eligible veterans, following regulatory changes.

• Pipeline includes expansion of funded care pathways with additional payers and geographies under consideration.